Can cabozantinib be reimbursed by medical insurance? Financial Burden and Solutions for Patients’ Medication

Cabozantinib is a multi-target tyrosine kinase inhibitor widely used in the treatment of renal cell carcinoma, hepatocellular carcinoma and medullary thyroid carcinoma. However, for many patients, in addition to the efficacy and side effects of the drug, one of the most concerning questions is: Can cabozantinib be reimbursed by medical insurance? The answer to this question is directly related to the financial burden on patients and the accessibility of treatment.

At present, the original drug of cabozantinib has not yet been marketed in China, and therefore has not been included in the national medical insurance directory. This means that if patients need to use cabozantinib, they can only purchase it through overseas channels, which undoubtedly increases economic pressure. The price of cabozantinib varies by region and purchase channel, but generally speaking, as an innovative targeted drug, its cost is relatively high, and long-term treatment may be a huge expense for ordinary families.

For patients who cannot be reimbursed by health insurance, there are alternatives that can be focused on to reduce the financial burden. For example, some patients can choose to participate in clinical trials, which not only provides free drug treatment but also contributes to medical research. In addition, some charities or pharmaceutical company assistance programs may also provide drug support or cost reductions to patients with financial difficulties. Patients can consult their attending doctor or relevant institutions to find out whether there is an assistance plan suitable for them.

Although cabozantinib is not yet included in medical insurance, with the continuous improvement of domestic pharmaceutical policies and the progress in the development of generic drugs, more lower-priced alternative drugs may be on the market in the future. In addition, the National Medical Insurance Directory is updated every year, and patients can continue to pay attention to relevant policy developments so that they can enjoy timely reimbursement benefits after the drugs are included in the medical insurance.

Reference:https://en.wikipedia.org/wiki/Cabozantinib